Phase 2 Study of Penpulimab with AVD for Newly Diagnosed Advanced Classic Hodgkin Lymphoma

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Penpulimab combined with AVD chemotherapy in patients newly diagnosed with advanced classic Hodgkin lymphoma. This is a randomized, open-label, multicenter phase II clinical trial focused on improving treatment outcomes for this condition. The study is sponsored by Sun Yat-sen University and aims to measure how well patients respond to these treatments over time. Participants are assigned to one of two treatment groups. One group receives Penpulimab and AVD injections together for six 28-day cycles, with doses on days 1 and 15 of each cycle. The other group receives Penpulimab alone for three cycles, followed by six cycles of AVD, and then Penpulimab again for three cycles, each cycle lasting 28 days with administration on days 1 and 15. These approaches are being compared to assess different schedules of this combination therapy. During the study, participants will undergo evaluations to measure their response to treatment, including the complete response rate from the first injection up to 24 or 48 weeks depending on the group. Researchers will also monitor progression-free survival, overall survival, and safety indicators for up to five years. The study includes regular assessments to track disease status and side effects, ensuring careful monitoring throughout the trial period.

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma